Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.-Reference-Cited by-同舟云学术

Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.

Published:2015-11-04 Issue:S2 Volume:3 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Ahmed Nabil,Brawley Vita,Hegde Meenakshi,Bielamowicz Kevin,Wakefield Amanda,Ghazi Alexia,Ashoori Aidin,Diouf Oumar,Gerken Claudia,Landi Daniel,Kalra Mamta,Yi Zhongzhen,Rooney Cliona,Dotti Gianpietro,Gee Adrian,Heslop Helen,Gottschalk Stephen,Powell Suzanne,Grossman Robert,Wels Winfried,Kew Yzonne,Baskin David,Zhang Jonathan,New Pamela,Hicks John

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/2051-1426-3-S2-O11.pdf

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current progress in chimeric antigen receptor T‐cell therapy for malignant tumors;MedComm – Future Medicine;2024-05-13

2. CAR-T Cell Therapy for Cancer;Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 );2024-04-15

3. Anti-Cancer Potential of Transiently Transfected HER2-Specific Human Mixed CAR-T and NK Cell Populations in Experimental Models: Initial Studies on Fucosylated Chondroitin Sulfate Usage for Safer Treatment;Biomedicines;2023-09-18

4. Tumor-associated macrophage-related strategies for glioma immunotherapy;npj Precision Oncology;2023-08-19

5. Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future;Cells;2023-07-03